AbbVie nears reported $10.9bn Apogee deal as zumilokibart heads toward Phase 3
AbbVie could pay a substantial premium for Apogee Therapeutics and its long-acting eczema antibody, but the reported deal depends on Phase 3 success and differentiation from established immunology drugs.